卡博替尼治疗晚期RET重排非小细胞肺癌:一项开放标签、单中心、2期、单臂试验
这项开放标签、单中心、2期、单臂试验纳入26例RET重排肺腺癌患者,给予卡博替尼60 mg口服每日一次。25例可评估患者中7例确认部分缓解,总体缓解率28%(95%CI 12-49)。常见3级治疗相关不良事件为脂肪酶升高4例(15%)、丙氨酸氨基转移酶升高2例(8%)等,19例(73%)因药物相关不良事件需减量。
要点
- 卡博替尼在RET重排肺腺癌中确认部分缓解7/25例,总体缓解率28%(95%CI 12-49)。
- 26例患者中19例(73%)因药物相关不良事件需减量,常见3级事件为脂肪酶升高4例(15%)。
- 无药物相关死亡,但随访期间16例(62%)患者死亡。
核心结论
- 卡博替尼在RET重排肺癌患者中报告的活性将RET重排定义为肺癌的可操作驱动因素。
- 需要更好地理解肿瘤生物学和新的治疗方法来改善RET定向靶向治疗的结局。
研究设计与样本
- 开放标签、Simon两阶段、单中心、2期、单臂试验,在美国开展。
- 纳入标准为携带RET重排的转移性或不可切除肺癌、Karnofsky体能状态高于70、可测量病灶。
- 患者口服卡博替尼60 mg每日一次。
- 主要目标为评估可评估患者的总体缓解(实体瘤疗效评价标准1.1版);可评估患者为至少接受一剂卡博替尼且在基线和至少一个方案指定随访时间点接受CT成像者。
- 安全性分析在至少接受一剂卡博替尼的改良意向治疗人群中进行。
主要发现
- KIF5B-RET为主要融合类型,见于16例(62%)患者。
- 研究达到主要终点,25例可评估患者中7例确认部分缓解,总体缓解率28%(95%CI 12-49)。
- 26例接受卡博替尼患者中,最常见3级治疗相关不良事件为脂肪酶升高4例(15%)、丙氨酸氨基转移酶升高2例(8%)、天冬氨酸氨基转移酶升高2例(8%)、血小板计数降低2例(8%)、低磷血症2例(8%)。
- 无药物相关死亡记录,但随访期间16例(62%)患者死亡。
- 19例(73%)患者因药物相关不良事件需减量。
关键数值与推荐
- 总体缓解率28%(95%CI 12-49),为25例可评估患者中7例确认部分缓解。
- 3级治疗相关不良事件:脂肪酶升高4例(15%)、丙氨酸氨基转移酶升高2例(8%)、天冬氨酸氨基转移酶升高2例(8%)、血小板计数降低2例(8%)、低磷血症2例(8%)。
- 19例(73%)患者因药物相关不良事件需减量。
- 随访期间16例(62%)患者死亡,无药物相关死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. METHODS: We enrolled patients in this open-label, Simon two-stage, single-centre, phase 2, single-arm trial in the USA if they met the following criteria: metastatic or unresectable lung cancer harbouring a RET rearrangement, Karnofsky performance status higher than 70, and measurable disease. Patients were given 60 mg of cabozantinib orally per day. The primary objective was to determine the overall response (Response Criteria Evaluation in Solid Tumors version 1.1) in assessable patients; those who received at least one dose of cabozantinib, and had been given CT imaging at baseline and at least one protocol-specified follow-up timepoint. We did safety analyses in the modified intention-to-treat population who received at least one dose of cabozantinib. The accrual of patients with RET-rearranged lung cancer to this protocol has been completed but the trial is still ongoing because several patients remain on active treatment. This study was registered with ClinicalTrials.gov, number NCT01639508. FINDINGS: Between July 13, 2012, and April 30, 2016, 26 patients with RET-rearranged lung adenocarcinomas were enrolled and given cabozantinib; 25 patients were assessable for a response. KIF5B-RET was the predominant fusion type identified in 16 (62%) patients. The study met its primary endpoint, with confirmed partial responses seen in seven of 25 response-assessable patients (overall response 28%, 95% CI 12-49). Of the 26 patients given cabozantinib, the most common grade 3 treatment-related adverse events were lipase elevation in four (15%) patients, increased alanine aminotransferase in two (8%) patients, increased aspartate aminotransferase in two (8%) patients, decreased platelet count in two (8%) patients, and hypophosphataemia in two (8%) patients. No drug-related deaths were recorded but 16 (62%) patients died during the course of follow-up. 19 (73%) patients required dose reductions due to drug-related adverse events. INTERPRETATION: The reported activity of cabozantinib in patients with RET-rearranged lung cancers defines RET rearrangements as actionable drivers in patients with lung cancers. An improved understanding of tumour biology and novel therapeutic approaches will be needed to improve outcomes with RET-directed targeted treatment. FUNDING: Exelixis, National Institutes of Health and National Cancer Institute Cancer Center Support Grant P30 CA008748.
引用
- Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016. PMID: 27825636. doi:10.1016/S1470-2045(16)30562-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。